EN DE
Watch Cansortium Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Cansortium Inc (CNTMF) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Cansortium Inc stock $0.02, price $0.02, upside +7.8%, quality 21 out of 100. Rating: fairly valued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · Home Canada · ISIN CA13809L1094

CI Cansortium Inc logo Thin data Nov 4, 2026

Cansortium Inc

CNTMF · US
Fairly valued, weak quality

The stock costs about what our calculation considers fair.

Fair value $0.0173 · Fairly valued
Expensive Growth (revenue 5y +10.6 %/yr in USD)
Negative equity (buybacks among others)
Revenue last quarter 25% below a year ago.
Quality 21/100
Loss-making · -105.5% net margin (TTM)
Negative free cash flow
Trails peers (2/7)
Narrow moat 9/100
Thin data
Watch Cansortium Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$0.9000 $0.0149 Fair Value $0.0173 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 4, 2026.

How to read this chart

60‑month range $0.0149 – $0.9000 · the $0.0160 price screens below the $0.0173 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 4, 2026.

Follow Cansortium in your weekly email

Every Wednesday you see whether Cansortium is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

FLUENT Corp., through its subsidiaries, cultivates, manufactures, processes, distributes, and sells medical cannabis products for medical and adult-use in the United States.

Show moreShow less

Its medical cannabis products are offered in oral drops, capsules, topicals, syringes, dried flower, pre-rolls, cartridges, concentrates, and edibles. The company also sells various third-party branded medical cannabis products, as well as other accessories.

It offers its products under the Bag-O, FLUENT, Hyer Kind, Knack, MOODS, and Wandr brands. The company was formerly known as Cansortium Inc. and changed its name to FLUENT Corp. in February 2025. FLUENT Corp. was founded in 2015 and is headquartered in Tampa, Florida.

Stock analysis

Cansortium Inc (CNTMF) currently trades at $0.0160, while our model-based Fair Value estimate is $0.0173, so the stock looks roughly fairly valued today (gap 7.2%).

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the data coverage at low.

Quality & growth

The Quality Score stands at 21/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Cansortium Inc reported revenue of $86.7M in FY2025 versus $65.4M in FY2021, a compound +7.3%/yr. Reported net income was −$72.5M in FY2025.

Key figures

Market cap $10.2M Micro · P/S ratio 0.13 · EPS (TTM) $−0.1600 · Net margin −83.6% · Return on equity −534% · Return on assets (EBIT) −0.4% (5-year average) · Operating margin −12.0% · Revenue (TTM) $76.0M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 9 out of 100 (medium confidence).

What moves the price

The share trades about 77% below its 52-week high and 7% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at 8%, CNTMF screens cheaper than that median.

Fair Value models

Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
EV/EBITDA n/a $0.0300 $0.0700 62
All 1 models by family
Multiples
EV/EBITDA n/a $0.0300 $0.0700 62

Open the full fair value analysis →

Quality Score breakdown

Overall quality 21/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 18
How much profit the company makes from its sales and capital
Quality Growth 23
Are margins and returns getting better?
Cashflow 4
Do the profits arrive as real cash?
Financial strength 3
Debt, balance sheet and risk of trouble
Investment 73
Does it invest with discipline instead of growing at any price?
Low Volatility 40
How calm the share price moves, does not count
Price momentum 5
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 1
Distance to the 52-week high, does not count
New shares 30
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 30/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−0.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−0.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.6%
Start year 2020 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+40.4%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−16.1% (2020) → −17.6% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch CNTMF, get fair value alerts →

Compare Cansortium Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 549 stocks

Beats the industry median on 2/7 measures
Overall it trails its industry peers.
Valuation
Quality Score 21 · Bottom 25%
Fair Value upside +8.1% · Above median
Profitability
Return on equity (12 months) Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Return on assets −48.8% · Bottom 25%
Net margin (12 months) −105.5% · Bottom 25%
Operating margin (12 months) −12.0% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −25.0% · Bottom 25%
Balance sheet
Debt / equity Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
P/S (12 months) 0.13× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)44 · sector 15
FUTURE (revenue growth)0 · sector 25
PAST (return on equity)0 · sector 29
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)0 · sector 32

PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $79.40 $113.53 +43% vs CNTMF
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥50.43 ¥55.21 +9% vs CNTMF
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,860 ₹1,947 +5% vs CNTMF
Haleon plc HLN $9.14 $8.61 −6% vs CNTMF
Merck KGaA MRK €148.75 €109.18 −27% vs CNTMF
Galderma Group GALD CHF 191.75 CHF 109.86 −43% vs CNTMF
Takeda Pharmaceutical Company TAK $21.02 $11.31 −46% vs CNTMF
Teva Pharmaceutical Industries Limited TEVA $42.61 $20.74 −51% vs CNTMF
Sandoz Group SDZ CHF 83.78 CHF 39.70 −53% vs CNTMF
Divi's Laboratories Limited DIVISLAB ₹10,321 ₹1,567 −85% vs CNTMF

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cansortium Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Cansortium Inc Fair Value". https://www.fairvalue-calculator.com/stock/CNTMF

Frequently asked questions

Is Cansortium Inc (CNTMF) overvalued or undervalued?
As of Nov 4, 2026, our model estimates a fair value of $0.0173 versus a price of $0.0160, about +8% upside (fairly valued).
What is the fair value of CNTMF?
Our model-based fair value for Cansortium Inc is $0.0173 (as of Nov 4, 2026), built from audited fundamentals. The current price: $0.0160.
What is the quality score of CNTMF?
Cansortium Inc has a Quality Score of 21/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Cansortium Inc (CNTMF)?
Our model-based price target is the fair value of $0.0173 (as of Nov 4, 2026) from 1 valuation models. It is a calculation from audited fundamentals, not an analyst target.
What is the Cansortium Inc stock forecast for 2026?
Our models put fair value at $0.0173, about +8% upside versus a price of $0.0160 (fairly valued). The calculation is refreshed regularly with new filings.
What is the revenue of Cansortium Inc (CNTMF)?
Cansortium Inc reported trailing-twelve-month revenue of about $76.0M (latest available figure, as of Nov 4, 2026).
What is the intrinsic value of Cansortium Inc (CNTMF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Cansortium Inc it is $0.0173 per share (as of Nov 4, 2026), against a price of $0.0160. It is the blended result of 1 valuation models in 1 family (Multiples).
Is Cansortium Inc stock overvalued or undervalued in 2026?
As of Nov 4, 2026, CNTMF trades below its calculated fair value: price $0.0160, fair value $0.0173, a gap of about +8% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CNTMF?
No. The price is what the market pays today ($0.0160); the fair value is what the company's own numbers justify ($0.0173). For Cansortium Inc the two are $0.0013 per share apart. That gap is exactly why we show both numbers side by side.
How much is Cansortium Inc worth?
The market values Cansortium Inc at about $10.2M (market capitalisation, as of Nov 4, 2026). Per share that is $0.0160; our models calculate a fair value of $0.0173 per share.
How solid is the balance sheet of Cansortium Inc (CNTMF)?
Balance-sheet figures for Cansortium Inc (as of Nov 4, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 21/100, which measures business quality independently of the share price.
How far is CNTMF from its 52-week high?
Cansortium Inc trades at $0.0160, about 77% below its 52-week high of $0.0700 and 7% above the low of $0.0149 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0173 is for.
Which stocks are comparable to Cansortium Inc?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Cansortium Inc stock attractive at the current price?
The data as of Nov 4, 2026: price $0.0160, calculated fair value $0.0173 (+8%), Quality Score 21/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of CNTMF calculated?
We run Cansortium Inc through 1 models from 1 family: Multiples. Every model gets the same audited fundamentals; the fair value of $0.0173 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Cansortium Inc currently trades 7% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Cansortium Inc (CNTMF)?
The closing price on Nov 6, 2026 was $0.0160. Our model-based fair value is $0.0173, about +8% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Cansortium Inc right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Cansortium Inc

How large is the market capitalisation of Cansortium Inc (CNTMF)?
The market capitalisation of Cansortium Inc is $10.2M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Cansortium Inc (CNTMF)?
The price-to-sales ratio of Cansortium Inc is 0.13 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Cansortium Inc (CNTMF)?
Earnings per share at Cansortium Inc are $−0.1600. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Cansortium Inc (CNTMF)?
The net margin of Cansortium Inc is −83.6% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Cansortium Inc (CNTMF)?
The return on equity (ROE) of Cansortium Inc is −534% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Cansortium Inc (CNTMF)?
On an EBIT basis the return on assets of Cansortium Inc is −0.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Cansortium Inc (CNTMF)?
The operating margin of Cansortium Inc is −12.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Cansortium Inc (CNTMF)?
Revenue at Cansortium Inc is growing −25.0% versus a year earlier (3y avg −0.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Cansortium Inc (CNTMF) generate?
The free cash flow of Cansortium Inc is −$15.0M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Cansortium Inc (CNTMF) carry?
The net debt of Cansortium Inc is $64.0M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Cansortium Inc in the live analysis

One click puts Cansortium Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.